



Article

Cell-Selective Altered Cargo Properties of Extracellular Vesicles Following In Vitro Exposures to Intermittent Hypoxia

David Sanz-Rubio ^{1,2} , Abdelnaby Khalyfa ^{1,*} , Zhuanhong Qiao ¹, Jorge Ullate ¹ , José M. Marin ^{2,3},
Leila Kheirandish-Gozal ¹ and David Gozal ^{1,†}

- ¹ Department of Child Health, Child Health Research Institute, University of Missouri School of Medicine, Columbia, MO 65201, USA; davidsanzrubio91@gmail.com (D.S.-R.); qiaoz@health.missouri.edu (Z.Q.); jullate92@gmail.com (J.U.); gozall@health.missouri.edu (L.K.-G.); gozald@health.missouri.edu (D.G.)
- ² Translational Research Unit, Hospital Universitario Miguel Servet, Instituto de Investigación Sanitaria de Aragón (IIS Aragón), 50009 Zaragoza, Spain; jmmarin@unizar.es
- ³ Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERes), 28029 Madrid, Spain
- * Correspondence: khalyfaa@missouri.edu; Tel.: +1-573-884-7685
- † These authors contributed equally to this work.

Abstract: Intermittent hypoxia (IH), a hallmark of obstructive sleep apnea (OSA), is associated with cardiovascular and metabolic dysfunction. However, the mechanisms underlying these morbidities remain poorly delineated. Extracellular vesicles (EVs) mediate intercellular communications, play pivotal roles in a multitude of physiological and pathological processes, and could mediate IH-induced cellular effects. Here, the effects of IH on human primary cells and the release of EVs were examined. Microvascular endothelial cells (HMVEC-d), THP1 monocytes, THP1 macrophages M0, THP1 macrophages M1, THP1 macrophages M2, pre-adipocytes, and differentiated adipocytes (HAd) were exposed to either room air (RA) or IH for 24 h. Secreted EVs were isolated and characterized using transmission electron microscopy, nanoparticle tracking analysis, and Western blotting. The effects of each of the cell-derived EVs on endothelial cell (EC) monolayer barrier integrity, on naïve THP1 macrophage polarity, and on adipocyte insulin sensitivity were also evaluated. IH did not alter EVs cell quantal release, but IH-EVs derived from HMVEC-d ($p < 0.01$), THP1 M0 ($p < 0.01$) and HAd ($p < 0.05$) significantly disrupted HMVEC-d monolayer integrity, particularly after H₂O₂ pre-conditioning. IH-EVs from HMVEC-d and THP1 M0 elicited M2-polarity changes did not alter insulin sensitivity responses. IH induces cell-selective changes in EVs cargo, which primarily seem to target the emergence of endothelial dysfunction. Thus, changes in EVs cargo from selected cell sources in vivo may play causal roles in some of the adverse outcomes associated with OSA.

Keywords: Intermittent hypoxia; extracellular vesicles (EVs); exosomes; OSA; cardiovascular disease; CVD; insulin resistance; adipocytes; macrophages; THP1 cells



Citation: Sanz-Rubio, D.; Khalyfa, A.; Qiao, Z.; Ullate, J.; Marin, J.M.; Kheirandish-Gozal, L.; Gozal, D. Cell-Selective Altered Cargo Properties of Extracellular Vesicles Following In Vitro Exposures to Intermittent Hypoxia. *Int. J. Mol. Sci.* **2021**, *22*, 5604. <https://doi.org/10.3390/ijms22115604>

Academic Editor: Emilia Pedone

Received: 25 April 2021

Accepted: 19 May 2021

Published: 25 May 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Obstructive sleep apnea (OSA) is a highly prevalent disease that is characterized by periodic collapse of the upper airway during sleep, and it is estimated to affect one billion people worldwide [1–3]. The repeated episodes of upper airway obstruction during sleep usually result in intermittent hypoxia (IH) and episodic arousals, adversely affecting the quality of sleep, and potentially increasing the risk for both cardiovascular and metabolic dysfunction [2,4–9]. Obesity is considered the most important risk factor for OSA, and further promotes the risk of associated morbidities [4,10]. Consequently, and if left untreated, OSA-induced adverse consequences include ischemic heart disease, systemic hypertension, cerebrovascular stroke, atrial fibrillation, diabetes and dyslipidaemias, neurocognitive and mood disorders, excessive daytime sleepiness, increased incidence of motor vehicle accidents, poor quality of life, and increased overall mortality [11–16].

In the context of OSA-induced atherosclerosis [16–18], endothelial cell dysfunction along with monocyte and macrophage activation play an important role in the initiation and progression of the atheroma plaque [19]. Additionally, several cellular and molecular mechanisms that lead to insulin resistance in the context of OSA have been reported [20–25]. To better understand the implications of OSA and its associated morbidities, a substantial effort in the generation of adequate animal models and cell culture systems that reliably mimic the human disease has occurred over the last several decades [9,26–29], and has led to the proposal of several mechanisms and molecular pathways [23,30,31].

Extracellular vesicles (EVs) are highly heterogeneous nanovesicles that differ in size and biogenesis pathways, and primarily include exosomes (30–150 nm), macrovesicles (100–1000 nm), and apoptotic bodies (800–5000 nm) [32–34]. EVs are involved in a large repertoire of organismal processes, particularly regulating cell-to-cell communication and function [35–37]. Communication from cell to cell is conveyed by the EVs cargo delivery to target cells via transfer microRNA (miRNA), proteins, RNA, DNA, or lipids [38–40], and such cargo is highly dynamic and can be altered in the context of cellular activation, stress, senescence, or hypoxia [41–44]. Although the specific roles of EVs in the context of OSA subjects have not been fully explored, initial work from our laboratory has shown that circulating EVs from patients with OSA promote endothelial and adipocyte dysfunction and accelerated senescence [9,21,28,37,45–48].

Intermittent hypoxia, one of the hallmarks of OSA, has now been firmly established as a dominant and major determinant of OSA-related morbidities [18]. Human and animal models of chronic IH seem to show a significant role for IH in the pathogenesis of OSA comorbidity [49,50]. It is being increasingly recognized that IH promotes increased oxidative stress, systemic and vascular inflammation with endothelial dysfunction, increased sympathetic activation, and BP elevations, thus contributing to multiorgan comorbidity [18,51–53]. In the present study, we hypothesized that IH exposures would promote changes in the EVs quantity and cargo (miRNA, mRNAs, proteins or lipids) secreted by cells closely related with the pathophysiology of OSA-associated comorbidities. Our aim was to assess the effects of IH on EVs released by endothelial cells, monocytes, naïve and polarized macrophages, pre-adipocytes, and adipocytes, and to explore selective functional aspects on these target cells that promote the occurrence of target organ dysfunction, such as atherosclerosis or insulin resistance.

2. Results

2.1. EVs Quantification and Characterization

EVs derived from different cell lines exposed to IH or RA were characterized using nanoparticle tracking analyzer (NTA), Western blots (WB), and transmission electron microscopy (TEM). Western blot (WB) confirmed the presence of CD63 and CD81 (exosome markers) and the absence of the Golgi apparatus marker GM130 in all EVs isolates (Figure 1A). These CD63 and CD81 proteins are part of tetraspanins super protein family and they are routinely used as positive exosome markers.

The effective size and concentrations range of EVs as determined by NTA and their individual values for each cell source and condition are presented in Figure 1B. Samples of EVs from the different cell sources displayed concentrations with a similar magnitude order, between 10^{10} and 10^{11} nanoparticles/mL. When comparing differences in EVs quantal release between RA and IH conditions, a significant increase in EVs was detected only among HMVEC-d exposed to ($p = 0.047$), with all other cells showing no significant differences. In terms of size distribution, EVs from all cell sources showed a diameter ranging between 35 and 150 nm and peaking between 100 and 135 nm, which is coherent with purified EVs. No differences were observed in EV size in relation to RA or IH exposures. Size and morphology of EVs were evaluated by TEM for all cell sources for both RA and IH conditions. The negative staining of electron microscopy (EM) for each EVs derived from each cell conditions is shown in Figure 1C. As expected from the NTA data, most of the vesicles found were between 30 and 150 nm, and they showed the typical

EVs morphology consistent with previously published sources [48,54]. No differences between RA and IH-derived EVs emerged for any of the cells evaluated herein. The only cell source that required a slightly different processing was human adipocyte, for which it was necessary to increase the concentration of the samples from 1:100 to 1:50 to visualize EVs using TEM.




Figure 1. Characterization of extracellular vesicles. (A) Western blots of protein markers corresponding to positive markers CD63 (53 KDa) and CD81 (26 KDa) and negative EV marker GM130 (132 kDa). (B) Nano tracking analysis (NTA) quantification and median size of the EVs from different cell sources in both conditions room air (RA) and intermittent hypoxia (IH). (C) Representative images of electron microscope from the EVs isolated from all cell sources after RA or IH exposure.

2.2. Effects of EVs on Endothelial Cell Monolayer Barrier Integrity

The effects of EVs from the various cell sources were evaluated under three different conditions. We first evaluated the role of EVs secreted under IH on endothelial dysfunction. This process constitutes an early step in the development of cardiovascular outcomes. The intermediate mechanisms that lead to those consequences are unknown in OSA, and EVs could be crucially involved. Second, we studied the effects of EVs on naïve macrophages; OSA, and more particularly the multiple cycles of IH during sleep, have been broadly associated with systemic low-grade inflammation. EVs could participate in this process through the regulation of both proinflammatory and anti-inflammatory pathways. Third, we also studied the effects of IH derived EVs on insulin sensitivity in naïve adipocytes; In addition to cardiovascular consequences, OSA has been linked with metabolic disorders. EVs could be involved in those metabolic adverse consequences by promoting the insulin resistance under IH conditions. As shown in Figure 2A, we compared the EVs produced

by the different cells in RA and IH conditions on a naïve endothelial cell barrier, on an endothelial cell barrier that was pre-treated with H₂O₂ for 6 h to promote endothelial cell damage, and on a naïve endothelial cell barrier that was treated with H₂O₂ 6 h after treatment with EVs.




Figure 2. Effect of extracellular vesicles (EVs) on naïve human microvascular endothelial cell (HMVEC - d) tight junction barrier function using ECIS array. (A) Graphical scheme of the analyses performed. (B) Results from ECIS array after directly exposure to EVs from the different cell sources exposure to both room air (RA, green) and intermittent hypoxia (IH, red). (C) Results from ECIS array preconditioned for 6 h with hydrogen peroxide and followed by treating cells with EVs from all cell origins both RA (green) and IH (red). (D) Results from ECIS array preconditioned with EVs from all cells sources both RA (green) and IH (red), and addition of hydrogen peroxide after 6 h. * indicates statistical significance, * $p < 0.05$, ** $p < 0.01$.

Next, Figure 2B shows the changes induced by EVs (from both RA and IH exposures) to the endothelial monolayer impedance normalized for the concurrent readings when no EVs were added. We observed that the barrier dysfunction induced by EVs from IH conditions was dependent on the cell source. Indeed, EVs secreted from HMVEC-d cells ($p < 0.01$), THP1 M0 ($p < 0.01$) and adipocytes ($p < 0.05$) under IH conditions damaged significantly the monolayer compared to RA, while the EVs derived from the other cell types were void of any effects. The treatment of the monolayer with H₂O₂ for 6 h prior to addition of EVs from diverse cell sources altered the monolayer resistance as shown Figure 2C. The first column of Figure 2C presents the damage induced with H₂O₂ without any EV treatment. After the pre-treatment with H₂O₂, HMVEC-d displayed also higher disruption of the endothelial layer in IH compared to RA ($p < 0.05$). Remarkably, the damage produced by HMVEC-d IH EVs was higher than without pre-treatment. The enhanced susceptibility to the EVs was similar in the EVs secreted by all THP1-derived cells, although in this case both RA and IH showed this increase ($p < 0.05$ in both). Finally, when we inverted the order of addition and treated first the endothelial monolayer with EVs for 6 h, and after that treated with H₂O₂, we did not observe any significant change between RA and IH EVs.

2.3. Effects of EVs on Naïve Macrophages

OSA, particularly their continuous cycles of IH during sleep, has been broadly associated with systemic low inflammation. EVs could participate in this process through

the regulation of both proinflammatory and anti-inflammatory pathways. In these experiments, we examined the polarity response of naïve THP1 macrophages after 24 of exposure to EVs from the various cell sources after either RA or IH exposures (Figure 3A).




Figure 3. Effect of extracellular vesicles (EVs) on naïve THP1 macrophages. (A) Graphical flowchart of the methods used. (B) Heat-map corresponding to the fold change between room air and intermittent hypoxia conditions analyzed in four pro-inflammatory genes (CCR7, IL6, TNF α and CXCL10) and three anti-inflammatory genes (IL10, DC-Sign and MRC1). * indicates statistical significance, * $p < 0.05$.

For this purpose, seven genes from macrophages exposed to EVs were evaluated, 4 of these genes were typical of M1 macrophage polarization and 3 were characteristic of M2 macrophage polarity. Figure 3B presents the fold change between IH-derived EVs versus RA-derived EVs for each cell source. IH EVs from HMVEC-d cells and THP1 M0 macrophages promoted M2 polarity in naïve M0 macrophages. Indeed, HMVEC-d IH EVs significantly reduced the pro-inflammatory gene IL6 and increased the anti-inflammatory gene IL10. THP1 M0 IH EVs increased the three anti-inflammatory genes IL10, DC-Sign and MRC-1, showing a significant upregulation of MRC-1 and DC-Sign and a trend towards

increased IL10 expression. The rest of the EVs from other cell sources showed divergent effects. IH EVs released by THP1 monocytes decreased expression of the pro-inflammatory genes, CCR7, IL6 and TNFA, but also decreased two of the anti-inflammatory genes, DC-Sign and MRC-1. THP1 M2 IH EVs significantly increased MRC-1 and showed a trend for increasing IL10, but also increased the expression of the pro-inflammatory gene CXCL10. IH EVs secreted by THP1 macrophage M1 and human adipocytes displayed the same profile, showing an increase in one of the anti-inflammatory genes, MRC-1, along with decreases in IL10. Finally, IH EVs from human pre-adipocytes did not show any change in the expression of anti- or pro-inflammatory genes.

Effects of IH derived EVs on insulin sensitivity in naïve adipocytes. In addition to cardiovascular consequences, OSA has been linked with metabolic disorders. EVs could be involved in those mechanisms promoting the insulin resistance under IH conditions. Therefore, we evaluated the changes in insulin induced pAkt/Akt ratio in naïve human adipocytes after 24-h treatment with EVs (Figure 4A). Figure 4C shows the results emanating from such EVs from all the cell sources for both RA and IH conditions. None of the EVs from any of the cells either exposed to IH or RA led to significant changes in insulin-induced pAkt/Akt ratios in naïve adipocytes.




Figure 4. Effect of extracellular vesicles (EVs) on naïve human adipocytes. (A) Graphical scheme of the analysis. (B) Representative image of bands obtained in the western blot for Akt and pAkt after treatment with EVs from human microvascular endothelial cells (HMVEC-d), THP1 monocytes (THP1 Mo), THP1 macrophages (THP1 M0), THP1 macrophages M1 stimulated (THP1 M1), THP1 macrophages M2 stimulated (THP1 M2), human pre-adipocytes (Pre-HAd) and human adipocytes (HAd) after both room air (R) and intermittent hypoxia (I) exposures. (C) Results obtained after quantifying the bands for the ratio pAkt/Akt for EVs from all cell sources after both room air (green) and intermittent hypoxia (red).

3. Discussion

The present study illustrates for the first time the specific and divergent effects of EVs-derived from different cell sources (human endothelial cells, adipocytes, monocytes and macrophages) following IH exposures, and their potential contributions to the adverse consequences commonly associated with OSA (i.e., vascular dysfunction, macrophage polarity changes, and insulin resistance). For example, EVs-derived from HMVEC-d, THP1 macrophages M0 and human adipocytes exposed to IH disrupt the naïve endothelial barrier. Contrary to our initial assumptions, EVs secreted by HMVEC-d and THP1 macrophages M0 exposed to IH promoted an anti-inflammatory profile, with other cells inducing a mixed effect. Furthermore, the ratio of pAKT/tAKT as indicator of insulin sensitivity remained unaltered after exposure to any of the EVs, irrespective of whether the cells had been exposed to IH or RA. Such findings, which are not aligned with the fact that circulating EVs in patients with OSA induce insulin resistance [21,55], suggest that other cells (for

example, platelets, lymphocytes, etc.) and possibly other factors that are present in OSA but not reflected in the *in vitro* IH exposures (e.g., sleep fragmentation) may be operationally involved. However, notwithstanding the dissimilarities between *in vitro* and *in vivo* EVs in the context of IH, the current experiments illustrate the potential contributory roles of EVs in OSA-induced morbidities. Our findings support the processes that occur in patients with OSA and their increased risk of developing endothelial dysfunction, atherosclerosis, and definitely other cardiovascular outcomes.

OSA is recognized as an important and independent risk factor for hypertension, coronary heart disease, stroke, mild cognitive dysfunction, and metabolic dysfunction [56,57]. The molecular pathways underlying the deleterious consequences of OSA are under investigations, however, the cellular and the molecular mechanisms remain poorly understood [51,58]. Some clinical and animal studies have demonstrated that endothelial dysfunction is a precursor of atherosclerosis, which is a pathological condition underlying cardiovascular diseases [59]. Of the several mechanisms activated by IH, oxidative stress and activation of inflammatory pathways have emerged as consistent players in endothelial dysfunction in both human and animal studies, as well as *in vitro* cellular experiments [25,37,60–71]. The common mechanisms linking IH, OSA and CVD are complex and likely mediated by multiple mechanisms. For example, human and animal studies have demonstrated that the pathophysiological changes brought on by OSA, including changes in intrathoracic pressures, hypoxia, and hypercapnia, which may cause structural and electrical changes that predispose to arrhythmia [72]. Additionally, hypoxia and hypercapnia associated with sleep apnea affect sympathetic nerve activity and cause vasoconstriction, and as a result hypertension may ensue, which is a known risk factor for atrial fibrillation [73,74]. Recently, mice exposed to CIH exhibit changes in the passive stiffness of the cardiac tissue extracellular matrix (ECM), a critical factor underlying conduction changes and predisposing to atrial fibrillation [75]. Furthermore, it has been shown that IH can contribute to a vasoconstrictive profile and to pathway-selective vascular IR through caveolin-1 overexpression, and its effect on nitric oxide metabolism [25]. Another mechanism of promotion of endothelial damage associated with IH is the increase in monocytic CCR5 gene expression and the enhanced RANTES-mediated chemotaxis and adhesion [67]. In addition, the serum of OSA patients displayed an inflammatory bioactivity after incubation with endothelial cells [70]. Those mechanisms are not only focused on endothelial cells, but also on other cell types in adipose tissue, the latter potentially playing a crucial role in the negative effects mediated by IH [71]. The cumulative findings from such studies have clearly identified that duration and severity of hypoxia are of great importance, that a multitude of pathways may be operationally recruited, and that interactions between different cells are also major determinants of the overall outcomes. Our data suggest that, at least *in vitro*, intermittent hypoxia, one of the main consequences of apneic events, is capable of inducing changes in EVs that would promote cardiovascular damage. Understanding of the CVD mechanisms in the context of OSA may allow for more direct targeting of specific pathophysiological contributors. Furthermore, new insights into the molecular pathophysiology of CVD open new opportunities in risk assessment and monitoring of therapeutic responses.

The opportunity to study human cells in culture can increase our insights into healthy and diseased states of the human body [76]. Significant efforts were made to accomplish relevant models of IH in cell cultures, and in parallel we have established a standard protocol for EVs isolation from different cell lines exposed to IH [28,29,54]. Several studies have reported about the release and the biogenesis of EVs *in vitro* cell cultures [77–80]. Thus, EVs are crucial in cell-to-cell communication, transferring the cells' phenotype from the origin cells to the receptor cells [81,82]. White adipose tissues-derived EVs showed immunomodulatory properties which convert macrophages towards a pro-inflammatory phenotype *in vitro*, and modulate insulin signaling in muscle and liver cells [79,83], 3T3-L1 cell adipocytes [84], and a human preadipocyte differentiated cell model [84]. In our study,

we are able to demonstrate that IH can partly reproduce intermediate mechanisms that in real life would be induced by IH in patients with OSA.

A number of studies have highlighted the potential contributions of EVs to human diseases, and OSA is not an exception. Studies on the involvement of EVs in the emergence of endothelial cell dysfunction and adipocyte insulin resistance in both patients suffering from OSA and animal models of OSA have provided robust initial evidence supporting such critical roles [9,21,28,55,64,85–94]. EV cargo is altered in response to hypoxia. For example, breast cancer cells released exosomes with high levels of miR-210 among their cargo under hypoxic conditions and hypoxic lung cancer cells showed increased levels of miR-23a [43,95]. Furthermore, pancreatic cancer cells increased the releasing of EV in hypoxia although decrease their size and hypoxia-resistant multiple myeloma cells produced higher concentration of exosomes compared to normoxic cells [81,95,96]. In the present study, although a slight increase of release in exosomes occurred after intermittent hypoxia exposure for most cell types, those changes did not reach statistical significance. This fact could be due to the intermittent nature of the hypoxia in our experiments. We therefore assume that most of the functional changes described as response to hypoxia in general, and particularly following IH, are caused by cargo alterations of the EVs, although further research is required in this field.

Endothelial cells play a key role in maintaining constant vascular tension, and vascular endothelial dysfunction, which is characterized by imbalanced vasoconstrictive and vasodilatory molecules, is the earliest sign of a vascular lesion preceding the occurrence of clinically obvious cardiovascular complications in OSA [17,19,97,98]. Hypoxia can also trigger complex intercellular communication, may aggravate endothelial dysfunction and destruction in early pre-atherosclerosis, and induce vascularization in cancer tissue and a progression of the disease [99–101]. In addition, hypoxic preconditioning for 24 h of mesenchymal stem cells improves their efficacy in the treatment of cardiovascular diseases [102]. It has been indicated that circulating EVs are in direct constant contact with endothelial cells and regulate endothelial cell proliferation, apoptosis, and migration, thus regulating vascular function [103]. Adipocyte EVs seems to play an important role in endothelium homeostasis, promoting under hypoxic conditions the leukocyte attachment via increasing the levels of PPAR γ among their cargo [104]. In addition, previously, we showed that EVs from OSA patient plasma impair endothelial adhesiveness and permeability [9,45,48] which may directly or indirectly trigger or exacerbate cellular endothelium, possibly via oxidative stress-related pathways. Our results suggest that endothelial dysfunction promoted by EVs as response to IH is not only stimulated by endothelial cells, but also by others such as macrophages or adipocytes.

Signaling and communication between endothelial cells and monocytes/macrophages play a critical role in cardiovascular homeostasis and the pathogenesis of atherosclerosis [105]. Macrophages have been categorized into two artificially distinct activation states designated as classical (M1) and alternative (M2), even though there is a much wider spectrum of combinations of the two putatively distinct macrophage phenotypes [106]. In addition to adipocyte-derived factors, an increased release of tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and additional products of macrophages and other cells that populate adipose tissue also play a role in the development of cardiovascular and metabolic risk including insulin resistance [107]. It has been described that under hypoxic conditions EVs produced by mesenchymal stem cells induced a shift toward a M2 differentiation in naïve macrophages [108]. In a similar trend, our study showed that EVs released by endothelial cells and macrophages during IH promote an anti-inflammatory status in naïve macrophages. Furthermore, the secretion of exosomes from adipose tissue macrophages regulates metabolic and inflammatory interactions between adipocytes and macrophages [109]. More recently, injection of secreted exosomes from M2 macrophages into obese mice improved insulin-glucose homeostasis without affecting adiposity [24].

Recently, we and others showed that EVs play a role in the development of the metabolic dysfunction by serving as a mode of intercellular communication among adipose tissue, liver, skeletal muscle, and immune cells [21,54,79,83,85]. In addition, EVs may play a role in the regulation of peripheral insulin sensitivity, a major component of the pathogenesis of multiple diseases by regulate insulin sensitivity through at least two different mechanisms, i.e., by modulating inflammation or by direct interaction with insulin-responsive organs [110]. In addition, hypoxia has been shown to promote changes in naïve adipocytes in their EVs that induce a reduction in the insulin-stimulated glucose uptake [111]. Our results show that the EVs produced under IH conditions by the different cell types do not modify the insulin resistance in naïve adipocytes, therefore, this effect described in association with OSA could be produced by other mechanisms rather than by the simple interactions of cells with IH-induced EVs cargo changes. We summarized the effects of IH on different cell sources and those of EVs and cardiovascular disease (Figure 5).




Figure 5. Schema illustrating the hypothetical role of EVs in OSA cardiometabolic consequences. Intermittent hypoxia as a resulting of OSA may alter the EVs cargo produced by different cell types as endothelial cells, macrophages, or adipocytes, modifying the communication between those cells, and promoting the cardiovascular comorbidities commonly associated with OSA and cardiometabolic consequences [21,46,47,60,109].

This study has several limitations. First, we used in vitro models, a relatively simple and minimalistic approach to evaluate the complex processes that occur in the organism. Our cell cultures were exposed individually to IH, without any interaction with another cell type. Although these experiments are required to examine the specific effects of EVs from each cell source, further research using co-cultures of different cell types in both

2D and 3D would be beneficial [112]. Second, the effects of IH in a cell culture system might be different from the IH that characterizes OSA patients, particularly the number of cycles of IH exposure. Indeed, we only exposed the cells for 24 h as compared to many months and years of IH exposure that occur in OSA patients during their sleep. In addition, other pathological process such as arousal and activation of sympathetic nervous system are acting in those patients and such events cannot be recapitulated in vitro. Finally, in this study we performed a limited number of functional assays. Specially, we only evaluated a specific set of inflammatory genes to evaluate the capacity of EVs to change the inflammatory status and we measured Akt/pAkt ratio changes to evaluate insulin resistance and the effects of EVs in promotion of metabolic dysfunction.

Finally, our results indicate the relevance of IH as an intermediate mechanism for the development of vascular involvement in OSA. The clinical implications of these findings include the need of an effective treatment of OSA. This should include the elimination of nocturnal hypoxemia. It is therefore imperative that the treatment (e.g., with continuous positive airway pressure) be effective. That is to say, there should not be any residual nocturnal hypoxemia in the context of good adherence. On the other hand, given the heterogeneity of OSA and its different degrees of IH severity, the effect of different hypoxemia-degrees and associated secreted EVs at the cellular level should be evaluated in future studies. This would allow for establishing risk stratification concerning hypoxemia data in the management of OSA patients

Exosomes play critical and important roles in the regulation of physiological and pathophysiological processes, recognition and diagnosis, and treatment of CVD [113]. Since exosomes are released by most cells and they are relatively stable in the blood circulation and biological fluids, they have a potential future for preventive and diagnostic applications, and can help to develop future interventions and clinical applications. Furthermore, exploring different cell sources for therapeutic EVs is of utmost interest, because the lipid and surface protein composition of exosomes may be crucial to their function, and preservation of these characteristics is very important [114]. Multiple efforts have focused on the development of diagnostic and therapeutic applications that are based on exosome cargo, primarily RNA encapsulated in exosomes or carried in other carrier subtypes [115]. These EVs are promising nanocarriers for clinical use. However, the clinical applications of EVs are still in a very early stage, and further investigations are required.

In summary, we have shown that in isolated cell culture conditions, specific cell types exposed to IH exhibit divergent changes in the EVs cargo they release and also differ in the functional properties in of their EVs cargo when such cargo is delivered to naïve cells. Intercellular signalling by EVs is a route of cell-cell crosstalk that allows cells to selectively deliver biological messages to specific recipient cells. EVs convey these messages through their distinct cargos consisting of cytokines, proteins, nucleic acids, and lipids, which they transport from the donor cell to the recipient cell. In cardiovascular disease, endothelial- and immune cell-derived EVs are emerging as key players in different stages of disease development. Endothelial cell dysfunction is a key element in the complex pathophysiology of atherogenesis and triggers the release of endothelial cell-derived EVs. However, the effects of EVs in CVD are extremely complex and depend on the cellular origin, the functional state of the releasing cells, the biological content, and the diverse recipient cells. In addition, EVs can mediate the cross-talk between adipose tissues and macrophages that facilitates the deregulation of immune and metabolic homeostasis, raising the potential opportunity for EVs-based therapeutics in obesity, diabetes, or in OSA-induced cardiometabolic disease. Our future work will focus on profiling the genomic, transcriptomic, proteomic, and lipidomic cargo of EVs derived from different endothelial cells and their interactions with other relevant cells under intermittent hypoxic conditions. Such information should help identify hypoxia-specific molecules contributing to end-organ damage in the context of OSA.

4. Materials and Methods

4.1. Human Endothelial Cells

Human microvascular endothelial cells- dermal (HMVEC-d) were purchased from Lonza (catalog # CC-2543; Lonza, Alpharetta, GA, USA). Cells were grown in endothelial growth medium (EGM-2-MV; Alpharetta, GA, USA) supplemented with 5% fetal bovine serum, FBS, (Life Technologies, Grand Island, NY, USA), and further incubated at 37 °C/5% CO₂ in cell culture incubator. The cells were trypsinized and centrifuged at 250× g for 5 min, diluted, and re-plated at appropriate densities. All cells were used before passage 4.

4.2. Human Monocytes (THP-1)

THP-1 cells, a human monocyte cell line, were purchased from American Type Culture Collection (ATCC TIB-202; ATCC, Baltimore, MD, USA). Cells were cultured in RPMI 1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10% FBS. All THP-1 derived cells were grown at 37 °C and 5% CO₂. THP-1 derived macrophages (M0) were obtained through differentiation with PMA (phorbol 12-myristate 13-acetate (Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 10 ng/mL in growth medium for 3 days. THP-1 cells were seeded in 6-well plates with a density of 1,500,000 cells per well. Polarization to M1 macrophages was carried out with IFN- γ and LPS at 25 ng/mL and 0.1 ng/mL respectively for 3 days. M2 polarized macrophages were obtained after 3 days of treatment with IL-4 and IL-10 at 25 ng/mL both.

4.3. Human Adipocytes

Human adipocytes (adipose derived stem cells, ADSCs) were purchased from Lonza (# PT-5006, Lonza, Alpharetta, GA, USA) and cultured at 37 °C and 5% CO₂ in pre-adipocyte basal media (PGM-2; Lonza, Alpharetta, GA, USA) supplemented with 10% FBS (Life Technologies, USA). Cells were seeded in 6-well plates with 350,000 cells O₂ per well in basal medium PGM-2, and after 24 h, cells were differentiated by changing to Bulletkit PGM-2 (PT-9502 & PT-8202; Lonza, USA) media containing 10% FBS, 1 μ g/mL insulin, 1 μ M dexamethasone (DEX), and 0.5 mM 3-isobutyl-1-methylxanthine. The medium was changed every 2 days for 12 days.

4.4. Intermittent Hypoxia (IH) Exposures

Exposures to normoxia and IH were carried out in 6-well plates for all cells. IH (5% O₂, 5% CO₂, and balance N₂ for 30 min alternating with 30-min normoxia (21% O₂, 5% CO₂, and balance N₂), using a custom-designed, computer-controlled incubation chamber attached to an external O₂-CO₂ computer-driven controller (Biospherix, Redfield, NY, USA) as previously described [116,117].

HMVEC-d and human pre-adipocytes were seeded with a density of 350,000 cells per well, and incubated in corresponding growth medium for 24 h until confluence. Then, cells were washed with non FBS medium and growth medium was replaced with the equivalent EGM-2 and PBM-2 supplemented with 5% and 10% depleted FBS (centrifuged overnight at 100,000× g) respectively. Human adipocytes obtained after differentiation were washed with non FBS medium and differentiation medium was substituted by PBM-2 supplemented with 10% depleted FBS. THP1 monocytes were centrifuged at 250× g for 5 min, washed with non FBS RPMI 1640 medium and centrifuged again. After that, they were plated at 1,500,000 cells per well in 10% depleted FBS RPMI 1640 medium and incubated for 2 h before starting the exposure. THP1 naïve macrophages (M0), M1 THP1 macrophages and M2 THP1 macrophages were washed once with non FBS RPMI 1640 medium and RPMI 1640 supplemented with 10% depleted FBS was added.

4.5. Isolation of Extracellular Vesicles (EVs)

EVs were isolated from the supernatants using the Total Exosome Isolation kit (Life Technologies, USA) per manufacturer's guidelines. All experiments were performed with EVs at a 1:100 dilution. Cell supernatants of the different cell types were centrifuged at

3000 × *g* and 4 °C for 30 min. Pellets were discarded and for each 1 mL of supernatant, 0.5 mL of precipitation buffer was added. The mix was vortexed and incubated overnight at 4 °C. The solution was then centrifuged at 10,000 × *g* and 4 °C for 1 h and 15 min and pellets were resuspended in fresh filtered (0.22 μm) Dulbecco's PBS (DPBS; Life Technologies, Grand Island, NY, USA). EVs stocks were stored at −20 °C.

4.6. Nano Tracking Analysis

Nanoparticle concentration and size distribution were determined using a Nanosight NS300 instrument (Malvern Instruments, Worcestershire, UK). All samples were diluted in PBS with 5 mM EDTA to a final volume of 1 mL. Dilution of EVs was adjusted based on the ideal number of particles per frame (20–100 particles/frame) by pretesting the samples. Camera levels were adjusted until all particles were distinctly visible and not exceeding particle signal saturation over 20% (level 13) according to the manufacturer's software manual (Nanosight NS300 User Manual, MAN0541-01-EN-00, 2017). For each measurement, five 1-min videos were captured at a temperature of 25 °C. After capture, videos were analyzed using NanoSight Software NTA 3.1.

4.7. Transmission Electron Microscopy

Isolated EVs solutions were diluted 1:100 in Dulbecco's PBS (DPBS; Life Technologies, Grand Island, NY, USA), and 5 μL of diluted exosomes were placed on parafilm before the Formvar/Carbon-coated grid are placed on top of exosome drops and allowed to stand for 2 min. Grids with adherent exosomes were washed three times with 30 μL DPBS drops and fixed with 2% paraformaldehyde in DPBS for 5 min. Finally, grids were incubated with 30 μL drops of 2% uranyl acetate and examined by electron microscopy [54]. The samples were washed with distilled water seven times (2 min each), and then they were viewed under a FEI Tecnai F30 Twin (Atlanta, GA, USA) transmission EM to measure the size of the isolated EVs [54].

4.8. Electric Cell-Substrate Impedance Sensing (ECIS) Endothelial Cell Assay

Endothelial cell monolayer barrier integrity was measured using the ECIS system (Applied Biophysics, Troy, NY, USA) which monitors the electrical impedance across small 250-micrometer diameter electrodes within wells used as substrates for cell growth. Baseline measurements were established for each array using culture medium (300 μL/well). HMVEC-d cells were seeded (70 × 105 cells/well) onto an 8W10E array and grown to confluence with media containing 5% depleted FBS. Once confluent, equivalent amounts of EVs were added into the wells, and trans-endothelial electrical resistance was monitored continuously for up to 40 h.

4.9. Effect of EVs on Macrophage Polarity

THP-1 monocytes were differentiated for 3 days as previously described in a 6-well plate with a density of 1,500,000 cells per well. Then, the media was replaced with RPMI 1640 supplemented with depleted FBS and EVs from the different cell sources were added to the naïve macrophages for 24 h. Supernatants were removed, and cells were collected with Qiazol (Qiagen, Germantown, MD, USA). Total RNA was isolated from THP-1 macrophages and prepared using RNeasy Lipid Tissue Mini Kit (Qiagen, Germantown, MD, USA) as described by the manufacturer's protocol. RT-qPCR analysis was performed for selected mRNAs using QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Hanover Park, IL, USA).

4.10. Effect of EVs on Insulin Sensitivity in Naïve Adipocytes

Human pre-adipocytes were grown in 12-well plates, and cells were differentiated as described above. By day 14 of differentiation, media were replaced with growth media containing 10% depleted FBS. Exosomes were added for 24 h and adipocytes were treated with 5 nm insulin (Sigma-Aldrich, USA) at 37 °C for 30 min. Adipocytes were rinsed with

cold PBS and 2% SDS (200 μ L). Protein concentrations of the cell lysates were determined using the BCA Kit (Life Technologies, Grand Island, NY, USA). The lysates were separated on Novex WedgeWell 12% Tris-Glycine gels (Life Technologies, Grand Island, NY, USA) and transferred to nitrocellulose membranes, incubated in blocking buffer (5% non-fat dry milk in TBST) followed by phosphoAkt (Ser473) antibody (Cell Signaling Technology, Danvers, MA, USA) or total Akt antibody (Cell Signaling Technology, US) overnight at 4 °C. Immunoreactive bands were visualized using an enhanced and quantified by the Image Lab software (Chemidoc XRS+; Bio-Rad, Hercules, CA, USA).

4.11. Statistical Analysis

Data are reported as mean \pm standard deviation (S.D.) unless otherwise indicated. Data presented are from at least 3–4 independent experiments. Statistical analyses were performed using GraphPad Prism V.8. Comparisons between groups were performed using unpaired Student *t*-tests. A two-tailed *P* value < 0.05 was defined as achieving statistical significance.

Author Contributions: Conceptualization, A.K., and D.G.; methodology, D.S.-R., A.K., J.U. and Z.Q.; software validation, D.S.-R. and A.K.; formal analysis, D.S.-R. and A.K.; investigation, A.K. and D.G.; resources, A.K., J.M.M., L.K.-G. and D.G; writing—original draft preparation, D.S.-R. and A.K.; writing—review and editing, D.S.-R., A.K., J.M.M., L.K.-G. and D.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Instituto Salud Carlos III-FEDER (FIS PI18/01524), L. Kheirandish-Gozal was supported by NIH grant HL130984 and by the Children’s Miracle Network Endowed Professorship. D. Gozal is supported by NIH grants HL140548, and AG061824. A.K., L.K.G. and D.G. are supported by Leda J. Sears Foundation grants, and by a Tier 2 grant from the University of Missouri.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data available on request.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Heinzer, R.; Vat, S.; Marques-Vidal, P.; Marti-Soler, H.; Andries, D.; Tobback, N.; Mooser, V.; Preisig, M.; Malhotra, A.; Waeber, G.; et al. Prevalence of sleep-disordered breathing in the general population: The HypnoLaus study. *Lancet Respir. Med.* **2015**, *3*, 310–318. [[CrossRef](#)]
2. Veasey, S.C.; Rosen, I.M. Obstructive Sleep Apnea in Adults. *N. Engl. J. Med.* **2019**, *380*, 1442–1449. [[CrossRef](#)]
3. Benjafield, A.V.; Ayas, N.T.; Eastwood, P.R.; Heinzer, R.; Ip, M.S.M.; Morrell, M.J.; Nunez, C.M.; Patel, S.R.; Penzel, T.; Pepin, J.L.; et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: A literature-based analysis. *Lancet Respir. Med.* **2019**, *7*, 687–698. [[CrossRef](#)]
4. Drager, L.F.; Togeiro, S.M.; Polotsky, V.Y.; Lorenzi-Filho, G. Obstructive sleep apnea: A cardiometabolic risk in obesity and the metabolic syndrome. *J. Am. Coll. Cardiol.* **2013**, *62*, 569–576. [[CrossRef](#)] [[PubMed](#)]
5. Jordan, A.S.; McSharry, D.G.; Malhotra, A. Adult obstructive sleep apnoea. *Lancet* **2014**, *383*, 736–747. [[CrossRef](#)]
6. Horne, R.S.C.; Ong, C.; Weichard, A.; Nixon, G.M.; Davey, M.J. Are there gender differences in the severity and consequences of sleep disordered in children? *Sleep Med.* **2020**, *67*, 147–155. [[CrossRef](#)] [[PubMed](#)]
7. Horne, R.S.C. Endothelial Damage in Children with Sleep-disordered Breathing. *Am. J. Respir. Crit. Care Med.* **2020**, *202*, 1497–1499. [[CrossRef](#)]
8. Horne, R.S.C. Consequences of paediatric sleep disordered breathing: Contributions from Australian and New Zealand investigators. *Sleep Med.* **2021**, *77*, 147–160. [[CrossRef](#)]
9. Khalyfa, A.; Gozal, D.; Chan, W.C.; Andrade, J.; Prasad, B. Circulating plasma exosomes in obstructive sleep apnoea and reverse dipping blood pressure. *Eur. Respir. J.* **2020**, *55*, 1901072. [[CrossRef](#)]
10. Mohit; Shrivastava, A.; Chand, P. Molecular determinants of obstructive sleep apnea. *Sleep Med.* **2021**, *80*, 105–112. [[CrossRef](#)]

11. Sánchez-de-la-Torre, M.; Khalyfa, A.; Sánchez-de-la-Torre, A.; Martínez-Alonso, M.; Martínez-García, M.Á.; Barceló, A.; Lloberes, P.; Campos-Rodríguez, F.; Capote, F.; Diaz-de-Atauri, M.J.; et al. Precision Medicine in Patients with Resistant Hypertension and Obstructive Sleep Apnea. *J. Am. Coll. Cardiol.* **2015**, *66*, 1023–1032. [[CrossRef](#)] [[PubMed](#)]
12. Evans, K.A.; Yap, T.; Turner, B. Screening Commercial Vehicle Drivers for Obstructive Sleep Apnea: Tools, Barriers, and Recommendations. *Workplace Health Saf.* **2017**, *65*, 487–492. [[CrossRef](#)] [[PubMed](#)]
13. Garbarino, S.; Durando, P.; Guglielmi, O.; Dini, G.; Bersi, F.; Fornarino, S.; Toletone, A.; Chiorri, C.; Magnavita, N. Sleep Apnea, Sleep Debt and Daytime Sleepiness Are Independently Associated with Road Accidents. A Cross-Sectional Study on Truck Drivers. *PLoS ONE* **2016**, *11*, e0166262. [[CrossRef](#)] [[PubMed](#)]
14. Khalyfa, A.; Qiao, Z.; Gileles-Hillel, A.; Khalyfa, A.A.; Akbarpour, M.; Popko, B.; Gozal, D. Activation of the Integrated Stress Response and Metabolic Dysfunction in a Murine Model of Sleep Apnea. *Am. J. Respir. Cell Mol. Biol.* **2017**, *57*, 477–486. [[CrossRef](#)]
15. Martínez, M.C.; Andriantsitohaina, R. Extracellular Vesicles in Metabolic Syndrome. *Circ. Res.* **2017**, *120*, 1674–1686. [[CrossRef](#)]
16. Yaggi, H.K.; Concato, J.; Kernan, W.N.; Lichtman, J.H.; Brass, L.M.; Mohsenin, V. Obstructive Sleep Apnea as a Risk Factor for Stroke and Death. *N. Engl. J. Med.* **2005**, *353*, 2034–2041. [[CrossRef](#)] [[PubMed](#)]
17. Marin, J.M.; Carrizo, S.J.; Vicente, E.; Agustí, A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. *Lancet* **2005**, *365*, 1046–1053. [[CrossRef](#)]
18. Dewan, N.A.; Nieto, F.J.; Somers, V.K. Intermittent Hypoxemia and OSA. *Chest* **2015**, *147*, 266–274. [[CrossRef](#)] [[PubMed](#)]
19. Gimbrone, M.A.; García-Cardena, G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circul. Res.* **2016**, *118*, 620–636. [[CrossRef](#)]
20. Coughlin, S.; Mawdsley, L.; Mugarza, J.A.; Calverley, P.M.A.; Wilding, J.P.H. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur. Heart J.* **2004**, *25*, 735–741. [[CrossRef](#)] [[PubMed](#)]
21. Khalyfa, A.; Gozal, D.; Masa, J.F.; Marin, J.M.; Qiao, Z.; Corral, J.; González, M.; Marti, S.; Kheirandish-Gozal, L.; Egea, C.; et al. Sleep-disordered breathing, circulating exosomes, and insulin sensitivity in adipocytes. *Int. J. Obesity* **2018**, *42*, 1127–1139. [[CrossRef](#)]
22. Ip, M.S.M.; Lam, B.; Ng, M.M.T.; Lam, W.K.; Tsang, K.W.T.; Lam, K.S.L. Obstructive Sleep Apnea Is Independently Associated with Insulin Resistance. *Am. J. Respir. Crit. Care Med.* **2002**, *165*, 670–676. [[CrossRef](#)]
23. Ryan, S.; Arnaud, C.; Fitzpatrick, S.F.; Gaucher, J.; Tamisier, R.; Pepin, J.L. Adipose tissue as a key player in obstructive sleep apnoea. *Eur. Respir. Rev.* **2019**, *28*, 190006. [[CrossRef](#)]
24. Ying, W.; Gao, H.; Dos Reis, F.C.G.; Bandyopadhyay, G.; Ofrecio, J.M.; Luo, Z.; Ji, Y.; Jin, Z.; Ly, C.; Olefsky, J.M. MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in obese mice. *Cell Metab.* **2021**, *33*, 781–790. [[CrossRef](#)]
25. Xiao, F.; Li, X.; Wang, J.; Cao, J. Mechanisms of vascular endothelial cell injury in response to intermittent and/or continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents. *Sleep Breath* **2019**, *23*, 515–522. [[CrossRef](#)]
26. Barros, D.; Garcia-Rio, F. Obstructive sleep apnea and dyslipidemia: From animal models to clinical evidence. *Sleep* **2019**, *42*, zsy236. [[CrossRef](#)]
27. Farre, R.; Montserrat, J.M.; Gozal, D.; Almendros, I.; Navajas, D. Intermittent Hypoxia Severity in Animal Models of Sleep Apnea. *Front. Physiol.* **2018**, *9*, 1556. [[CrossRef](#)]
28. Khalyfa, A.; Marin, J.M.; Qiao, Z.; Rubio, D.S.; Kheirandish-Gozal, L.; Gozal, D. Plasma exosomes in OSA patients promote endothelial senescence: Effect of long-term adherent continuous positive airway pressure. *Sleep* **2020**, *43*, zsz217. [[CrossRef](#)]
29. Khalyfa, A.; Gozal, D.; Kheirandish-Gozal, L. Plasma Extracellular Vesicles in Children with OSA Disrupt Blood-Brain Barrier Integrity and Endothelial Cell Wound Healing in Vitro. *Int. J. Mol. Sci.* **2019**, *20*, 6233. [[CrossRef](#)]
30. Javaheri, S.; Barbe, F.; Campos-Rodríguez, F.; Dempsey, J.A.; Khayat, R.; Javaheri, S.; Malhotra, A.; Martínez-García, M.A.; Mehra, R.; Pack, A.I.; et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. *J. Am. Coll. Cardiol.* **2017**, *69*, 841–858. [[CrossRef](#)]
31. Tudorache, V.; Traila, D.; Marc, M.; Oancea, C.; Manolescu, D.; Tudorache, E.; Timar, B.; Albai, A.; Fira-Mladinescu, O. Impact of moderate to severe obstructive sleep apnea on the cognition in idiopathic pulmonary fibrosis. *PLoS ONE* **2019**, *14*, e0211455. [[CrossRef](#)] [[PubMed](#)]
32. Théry, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* **2009**, *9*, 581–593. [[CrossRef](#)]
33. Mathivanan, S.; Ji, H.; Simpson, R.J. Exosomes: Extracellular organelles important in intercellular communication. *J. Proteomics* **2010**, *73*, 1907–1920. [[CrossRef](#)]
34. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. *Trends Cell Biol.* **2015**, *25*, 364–372. [[CrossRef](#)]
35. Tetta, C.; Ghigo, E.; Silengo, L.; Deregibus, M.C.; Camussi, G. Extracellular vesicles as an emerging mechanism of cell-to-cell communication. *Endocrine* **2013**, *44*, 11–19. [[CrossRef](#)] [[PubMed](#)]
36. Khalyfa, A.; Gozal, D. Exosomal miRNAs as potential biomarkers of cardiovascular risk in children. *J. Transl. Med.* **2014**, *12*, 162. [[CrossRef](#)]
37. Khalyfa, A.; Castro-Grattoni, A.L.; Gozal, D. Cardiovascular morbidities of obstructive sleep apnea and the role of circulating extracellular vesicles. *Ther. Adv. Respir. Dis.* **2019**, *13*, 1753466619895229. [[CrossRef](#)]

38. Pathan, M.; Fonseka, P.; Chitti, S.V.; Kang, T.; Sanwlani, R.; Van Deun, J.; Hendrix, A.; Mathivanan, S. Vesiclepedia 2019: A compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. *Nucleic Acids Res.* **2019**, *47*, D516–D519. [[CrossRef](#)] [[PubMed](#)]
39. Nicolini, A.; Ferrari, P.; Biava, P.M. Exosomes and Cell Communication: From Tumour-Derived Exosomes and Their Role in Tumour Progression to the Use of Exosomal Cargo for Cancer Treatment. *Cancers* **2021**, *13*, 822. [[CrossRef](#)]
40. Anand, S.; Samuel, M.; Kumar, S.; Mathivanan, S. Ticket to a bubble ride: Cargo sorting into exosomes and extracellular vesicles. *Biochim. Biophys. Acta Proteins Proteom.* **2019**, *1867*, 140203. [[CrossRef](#)]
41. Kanemoto, S.; Nitani, R.; Murakami, T.; Kaneko, M.; Asada, R.; Matsuhisa, K.; Saito, A.; Imaizumi, K. Multivesicular body formation enhancement and exosome release during endoplasmic reticulum stress. *Biochem. Biophys. Res. Commun.* **2016**, *480*, 166–172. [[CrossRef](#)]
42. Xu, H.; Ling, M.; Xue, J.; Dai, X.; Sun, Q.; Chen, C.; Liu, Y.; Zhou, L.; Liu, J.; Luo, F.; et al. Exosomal microRNA-21 derived from bronchial epithelial cells is involved in aberrant epithelium-fibroblast cross-talk in COPD induced by cigarette smoking. *Theranostics* **2018**, *8*, 5419–5433. [[CrossRef](#)]
43. King, H.W.; Michael, M.Z.; Gleadle, J.M. Hypoxic enhancement of exosome release by breast cancer cells. *BMC Cancer* **2012**, *12*, 421. [[CrossRef](#)]
44. Takasugi, M.; Okada, R.; Takahashi, A.; Virya Chen, D.; Watanabe, S.; Hara, E. Small extracellular vesicles secreted from senescent cells promote cancer cell proliferation through EphA2. *Nat. Commun.* **2017**, *8*, 15729. [[CrossRef](#)] [[PubMed](#)]
45. Khalyfa, A.; Zhang, C.; Khalyfa, A.A.; Foster, G.E.; Beaudin, A.E.; Andrade, J.; Hanly, P.J.; Poulin, M.J.; Gozal, D. Effect on Intermittent Hypoxia on Plasma Exosomal Micro RNA Signature and Endothelial Function in Healthy Adults. *Sleep* **2016**, *39*, 2077–2090. [[CrossRef](#)] [[PubMed](#)]
46. Khalyfa, A.; Kheirandish-Gozal, L.; Gozal, D. Exosome and Macrophage Crosstalk in Sleep-Disordered Breathing-Induced Metabolic Dysfunction. *Int. J. Mol. Sci.* **2018**, *19*, 3383. [[CrossRef](#)]
47. Khalyfa, A.; Gozal, D.; Kheirandish-Gozal, L. Plasma Exosomes Disrupt the Blood-Brain Barrier in Children with Obstructive Sleep Apnea and Neurocognitive Deficits. *Am. J. Respir. Crit. Care Med.* **2018**, *197*, 1073–1076. [[CrossRef](#)]
48. Khalyfa, A.; Kheirandish-Gozal, L.; Khalyfa, A.A.; Philby, M.F.; Alonso-Álvarez, M.L.; Mohammadi, M.; Bhattacharjee, R.; Terán-Santos, J.; Huang, L.; Andrade, J.; et al. Circulating Plasma Extracellular Microvesicle MicroRNA Cargo and Endothelial Dysfunction in Children with Obstructive Sleep Apnea. *Am. J. Respir. Crit. Care Med.* **2016**, *194*, 1116–1126. [[CrossRef](#)]
49. Nieto, F.J.; Peppard, P.E.; Young, T.; Finn, L.; Hla, K.M.; Farre, R. Sleep-disordered breathing and cancer mortality: Results from the Wisconsin Sleep Cohort Study. *Am. J. Respir. Crit. Care Med.* **2012**, *186*, 190–194. [[CrossRef](#)]
50. Tamisier, R.; Pepin, J.L.; Remy, J.; Baguet, J.P.; Taylor, J.A.; Weiss, J.W.; Levy, P. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. *Eur. Respir. J.* **2011**, *37*, 119–128. [[CrossRef](#)]
51. Drager, L.F.; Jun, J.C.; Polotsky, V.Y. Metabolic consequences of intermittent hypoxia: Relevance to obstructive sleep apnea. *Best Pract. Res. Clin. Endocrinol. Metab.* **2010**, *24*, 843–851. [[CrossRef](#)]
52. Gileles-Hillel, A.; Almendros, I.; Khalyfa, A.; Zhang, S.X.; Wang, Y.; Gozal, D. Early intermittent hypoxia induces proatherogenic changes in aortic wall macrophages in a murine model of obstructive sleep apnea. *Am. J. Respir. Crit. Care Med.* **2014**, *190*, 958–961. [[CrossRef](#)]
53. Castro-Grattoni, A.L.; Alvarez-Buue, R.; Torres, M.; Farre, R.; Montserrat, J.M.; Dalmasas, M.; Almendros, I.; Barbe, F.; Sanchez-de-la-Torre, M. Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a Mouse Model of Sleep Apnea. *Chest* **2016**, *149*, 1400–1408. [[CrossRef](#)]
54. Khalyfa, A.; Gaddameedhi, S.; Crooks, E.; Zhang, C.; Li, Y.; Qiao, Z.; Trzepizur, W.; Kay, S.A.; Andrade, J.; Satterfield, B.C.; et al. Circulating Exosomal miRNAs Signal Circadian Misalignment to Peripheral Metabolic Tissues. *Int. J. Mol. Sci.* **2020**, *21*, 6396. [[CrossRef](#)]
55. Khalyfa, A.; Ericsson, A.; Qiao, Z.; Almendros, I.; Farre, R.; Gozal, D. Circulating exosomes and gut microbiome induced insulin resistance in mice exposed to intermittent hypoxia: Effects of physical activity. *EBioMedicine* **2021**, *64*, 103208. [[CrossRef](#)]
56. Martin, M.S.; Sforza, E.; Roche, F.; Barthelemy, J.C.; Thomas-Anterion, C.; PROOF Study Group. Sleep breathing disorders and cognitive function in the elderly: An 8-year follow-up study. The proof-synapse cohort. *Sleep* **2015**, *38*, 179–187.
57. Castaneda, A.; Jauregui-Maldonado, E.; Ratnani, I.; Varon, J.; Surani, S. Correlation between metabolic syndrome and sleep apnea. *World J. Diabetes* **2018**, *9*, 66–71. [[CrossRef](#)]
58. O'Donnell, C.P. Metabolic consequences of intermittent hypoxia. *Adv. Exp. Med. Biol.* **2007**, *618*, 41–49.
59. Song, D.; Fang, G.; Greenberg, H.; Liu, S.F. Chronic intermittent hypoxia exposure-induced atherosclerosis: A brief review. *Immunol. Res.* **2015**, *63*, 121–130. [[CrossRef](#)]
60. Li, Y.; Zhang, H.; Du, Y.; Peng, L.; Qin, Y.; Liu, H.; Ma, X.; Wei, Y. Extracellular vesicle microRNA cargoes from intermittent hypoxia-exposed cardiomyocytes and their effect on endothelium. *Biochem. Biophys. Res. Commun.* **2021**, *548*, 182–188. [[CrossRef](#)] [[PubMed](#)]
61. Turnbull, C.D. Intermittent hypoxia, cardiovascular disease and obstructive sleep apnoea. *J. Thorac. Dis.* **2018**, *10* (Suppl. S1), S33–S39. [[CrossRef](#)] [[PubMed](#)]
62. Yan, Y.R.; Zhang, L.; Lin, Y.N.; Sun, X.W.; Ding, Y.J.; Li, N.; Li, H.P.; Li, S.Q.; Zhou, J.P.; Li, Q.Y. Chronic intermittent hypoxia-induced mitochondrial dysfunction mediates endothelial injury via the TXNIP/NLRP3/IL-1beta signaling pathway. *Free Radic. Biol Med.* **2021**, *165*, 401–410. [[CrossRef](#)] [[PubMed](#)]

63. Guo, H.; Ding, H.; Yan, Y.; Chen, Q.; Zhang, J.; Chen, B.; Cao, J. Intermittent hypoxia-induced autophagy via AMPK/mTOR signaling pathway attenuates endothelial apoptosis and dysfunction in vitro. *Sleep Breath* **2021**, 1–7. [[CrossRef](#)]
64. Peng, L.; Li, Y.; Li, X.; Du, Y.; Li, L.; Hu, C.; Zhang, J.; Qin, Y.; Wei, Y.; Zhang, H. Extracellular Vesicles Derived from Intermittent Hypoxia-Treated Red Blood Cells Impair Endothelial Function Through Regulating eNOS Phosphorylation and ET-1 Expression. *Cardiovasc. Drugs Ther.* **2020**, *26*, 1–13.
65. Wang, J.; Wang, J.; Li, X.; Hou, W.; Cao, J.; Feng, J. Endothelial Dysfunction in a Cell Culture Model Exposed to Various Intermittent Hypoxia Modes. *High Alt. Med. Biol.* **2020**, *21*, 388–395. [[CrossRef](#)]
66. Zhu, J.; Kang, J.; Li, X.; Wang, M.; Shang, M.; Luo, Y.; Xiong, M.; Hu, K. Chronic intermittent hypoxia vs chronic continuous hypoxia: Effects on vascular endothelial function and myocardial contractility. *Clin. Hemorheol. Microcirc.* **2020**, *74*, 417–427. [[CrossRef](#)]
67. Chuang, L.P.; Chen, N.H.; Lin, S.W.; Hu, H.C.; Kao, K.C.; Li, L.F.; Yang, C.T.; Huang, C.C.; Pang, J.S. Monocytic C-C chemokine receptor 5 expression increases in in vitro intermittent hypoxia condition and in severe obstructive sleep apnea patients. *Sleep Breath* **2019**, *23*, 1177–1186. [[CrossRef](#)] [[PubMed](#)]
68. Kochan-Jamroz, K.; Krolczewski, J.; Moszynska, A.; Collawn, J.F.; Bartoszewski, R. miRNA networks modulate human endothelial cell adaptation to cyclic hypoxia. *Cell Signal.* **2019**, *54*, 150–160. [[CrossRef](#)]
69. Sharma, P.; Dong, Y.; Somers, V.K.; Peterson, T.E.; Zhang, Y.; Wang, S.; Li, G.; Singh, P. Intermittent hypoxia regulates vasoactive molecules and alters insulin-signaling in vascular endothelial cells. *Sci. Rep.* **2018**, *8*, 14110. [[CrossRef](#)]
70. Zychowski, K.E.; Sanchez, B.; Pedrosa, R.P.; Lorenzi-Filho, G.; Drager, L.F.; Polotsky, V.Y.; Campen, M.J. Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells. *Atherosclerosis* **2016**, *254*, 59–66. [[CrossRef](#)]
71. Lee, M.Y.; Wang, Y.; Mak, J.C.; Ip, M.S. Intermittent hypoxia induces NF-kappaB-dependent endothelial activation via adipocyte-derived mediators. *Am. J. Physiol. Cell Physiol.* **2016**, *310*, C446–C455. [[CrossRef](#)]
72. Marulanda-Londono, E.; Chaturvedi, S. The Interplay between Obstructive Sleep Apnea and Atrial Fibrillation. *Front. Neurol.* **2017**, *8*, 668. [[CrossRef](#)] [[PubMed](#)]
73. Neilan, T.G.; Farhad, H.; Dodson, J.A.; Shah, R.V.; Abbasi, S.A.; Bakker, J.P.; Michaud, G.F.; van der Geest, R.; Blankstein, R.; Steigner, M.; et al. Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation. *J. Am. Heart Assoc.* **2013**, *2*, e000421. [[CrossRef](#)] [[PubMed](#)]
74. Holmqvist, F.; Guan, N.; Zhu, Z.; Kowey, P.R.; Allen, L.A.; Fonarow, G.C.; Hylek, E.M.; Mahaffey, K.W.; Freeman, J.V.; Chang, P.; et al. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Am. Heart J.* **2015**, *169*, 647–654. [[CrossRef](#)]
75. Farre, N.; Otero, J.; Falcones, B.; Torres, M.; Jorba, I.; Gozal, D.; Almendros, I.; Farre, R.; Navajas, D. Intermittent Hypoxia Mimicking Sleep Apnea Increases Passive Stiffness of Myocardial Extracellular Matrix. A Multiscale Study. *Front. Physiol.* **2018**, *9*, 1143. [[CrossRef](#)] [[PubMed](#)]
76. Holloway, E.M.; Capeling, M.M.; Spence, J.R. Biologically inspired approaches to enhance human organoid complexity. *Development* **2019**, *15*, 146. [[CrossRef](#)] [[PubMed](#)]
77. Hosseini-Beheshti, E.; Pham, S.; Adomat, H.; Li, N.; Tomlinson Guns, E.S. Exosomes as biomarker enriched microvesicles: Characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. *Mol. Cell Proteomics* **2012**, *11*, 863–885. [[CrossRef](#)]
78. Wynn, T.A.; Chawla, A.; Pollard, J.W. Macrophage biology in development, homeostasis and disease. *Nature* **2013**, *496*, 445–455. [[CrossRef](#)]
79. Kranendonk, M.E.; Visseren, F.L.; van Balkom, B.W.; Nolte-t Hoen, E.N.; van Herwaarden, J.A.; de Jager, W.; Schipper, H.S.; Brenkman, A.B.; Verhaar, M.C.; Wauben, M.H.; et al. Human adipocyte extracellular vesicles in reciprocal signaling between adipocytes and macrophages. *Obesity* **2014**, *22*, 1296–1308. [[CrossRef](#)]
80. Deng, Z.B.; Poliakov, A.; Hardy, R.W.; Clements, R.; Liu, C.; Liu, Y.; Wang, J.; Xiang, X.; Zhang, S.; Zhuang, X.; et al. Adipose tissue exosome-like vesicles mediate activation of macrophage-induced insulin resistance. *Diabetes* **2009**, *58*, 2498–2505. [[CrossRef](#)]
81. Patton, M.C.; Zubair, H.; Khan, M.A.; Singh, S.; Singh, A.P. Hypoxia alters the release and size distribution of extracellular vesicles in pancreatic cancer cells to support their adaptive survival. *J. Cell Biochem.* **2020**, *121*, 828–839. [[CrossRef](#)] [[PubMed](#)]
82. Wang, X.; Luo, G.; Zhang, K.; Cao, J.; Huang, C.; Jiang, T.; Liu, B.; Su, L.; Qiu, Z. Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kgamma to Promote Pancreatic Cancer Metastasis. *Cancer Res.* **2018**, *78*, 4586–4598. [[CrossRef](#)] [[PubMed](#)]
83. Kranendonk, M.E.; Visseren, F.L.; van Herwaarden, J.A.; Nolte-t Hoen, E.N.; de Jager, W.; Wauben, M.H.; Kalkhoven, E. Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells. *Obesity* **2014**, *22*, 2216–2223. [[CrossRef](#)] [[PubMed](#)]
84. Connolly, K.D.; Guschina, I.A.; Yeung, V.; Clayton, A.; Draman, M.S.; Von Ruhland, C.; Ludgate, M.; James, P.E.; Rees, D.A. Characterisation of adipocyte-derived extracellular vesicles released pre- and post-adipogenesis. *J. Extracell Vesicles* **2015**, *4*, 29159. [[CrossRef](#)] [[PubMed](#)]

85. Khalyfa, A.; Poroyko, V.A.; Qiao, Z.; Gileles-Hillel, A.; Khalyfa, A.A.; Akbarpour, M.; Almendros, I.; Farre, R.; Gozal, D. Exosomes and Metabolic Function in Mice Exposed to Alternating Dark-Light Cycles Mimicking Night Shift Work Schedules. *Front. Physiol.* **2017**, *8*, 882. [[CrossRef](#)]
86. Tan, J.; Xing, H.; Sha, S.; Li, J.; Miao, Y.; Zhang, Q. Analysis of Circulating Microvesicles Levels and Effects of Associated Factors in Elderly Patients with Obstructive Sleep Apnea. *Front. Aging Neurosci.* **2021**, *13*, 609282. [[CrossRef](#)] [[PubMed](#)]
87. Zhang, H.; Yang, F.; Guo, Y.; Wang, L.; Fang, F.; Wu, H.; Nie, S.; Wang, Y.; Fung, M.L.; Huang, Y.; et al. The contribution of chronic intermittent hypoxia to OSAHS: From the perspective of serum extracellular microvesicle proteins. *Metabolism* **2018**, *85*, 97–108. [[CrossRef](#)]
88. Jia, L.; Fan, J.; Cui, W.; Liu, S.; Li, N.; Lau, W.B.; Ma, X.; Du, J.; Nie, S.; Wei, Y. Endothelial Cell-Derived Microparticles from Patients with Obstructive Sleep Apnea Hypoxia Syndrome and Coronary Artery Disease Increase Aortic Endothelial Cell Dysfunction. *Cell Physiol. Biochem.* **2017**, *43*, 2562–2570. [[CrossRef](#)]
89. Ayers, L.; Turnbull, C.; Petousi, N.; Ferry, B.; Kohler, M.; Stradling, J. Withdrawal of Continuous Positive Airway Pressure Therapy for 2 Weeks in Obstructive Sleep Apnoea Patients Results in Increased Circulating Platelet and Leucocyte-Derived Microvesicles. *Respiration* **2016**, *91*, 412–413. [[CrossRef](#)]
90. Trzepizur, W.; Martinez, M.C.; Priou, P.; Andriantsitohaina, R.; Gagnadoux, F. Microparticles and vascular dysfunction in obstructive sleep apnoea. *Eur. Respir. J.* **2014**, *44*, 207–216. [[CrossRef](#)] [[PubMed](#)]
91. Tual-Chalot, S.; Gagnadoux, F.; Trzepizur, W.; Priou, P.; Andriantsitohaina, R.; Martinez, M.C. Circulating microparticles from obstructive sleep apnea syndrome patients induce endothelin-mediated angiogenesis. *Biochim. Biophys. Acta* **2014**, *1842*, 202–207. [[CrossRef](#)]
92. Stiefel, P.; Sanchez-Armengol, M.A.; Villar, J.; Vallejo-Vaz, A.; Moreno-Luna, R.; Capote, F. Obstructive sleep apnea syndrome, vascular pathology, endothelial function and endothelial cells and circulating microparticles. *Arch. Med. Res.* **2013**, *44*, 409–414. [[CrossRef](#)] [[PubMed](#)]
93. Salinari, R.K.; Filippo, C.; Claudio, C. Preliminary survival analysis of AIDS data from Goma, Zaire. *Trop. Doct.* **1990**, *20*, 169–170. [[PubMed](#)]
94. Wood, D.P., Jr.; Montie, J.E.; Pontes, J.E.; VanderBrug Medendorp, S.; Levin, H.S. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. *J. Urol.* **1989**, *141*, 346–349. [[CrossRef](#)]
95. Hsu, Y.L.; Hung, J.Y.; Chang, W.A.; Lin, Y.S.; Pan, Y.C.; Tsai, P.H.; Wu, C.Y.; Kuo, P.L. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. *Oncogene* **2017**, *36*, 4929–4942. [[CrossRef](#)]
96. Umezu, T.; Tadokoro, H.; Azuma, K.; Yoshizawa, S.; Ohyashiki, K.; Ohyashiki, J.H. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. *Blood* **2014**, *124*, 3748–3757. [[CrossRef](#)]
97. Atkeson, A.; Yeh, S.Y.; Malhotra, A.; Jelic, S. Endothelial function in obstructive sleep apnea. *Prog. Cardiovasc. Dis.* **2009**, *51*, 351–362. [[CrossRef](#)] [[PubMed](#)]
98. Trzepizur, W.; Priou, P.; Meslier, N.; Urban, T.; Martinez, M.C.; Andriantsitohaina, R.; Gagnadoux, F. Vascular dysfunction in obstructive sleep apnoea: Implication of microparticules. *Rev. Pneumol. Clin.* **2017**, *73*, 306–308. [[CrossRef](#)]
99. Bister, N.; Pistono, C.; Huremagic, B.; Jolkkonen, J.; Giugno, R.; Malm, T. Hypoxia and extracellular vesicles: A review on methods, vesicular cargo and functions. *J. Extracell. Vesicles* **2020**, *10*, e12002. [[CrossRef](#)]
100. Jain, R.K. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. *Cancer Cell* **2014**, *26*, 605–622. [[CrossRef](#)]
101. Tuleta, I.; Franca, C.N.; Wenzel, D.; Fleischmann, B.; Nickenig, G.; Werner, N.; Skowasch, D. Intermittent Hypoxia Impairs Endothelial Function in Early Preatherosclerosis. *Adv. Exp. Med. Biol.* **2015**, *858*, 1–7. [[PubMed](#)]
102. Hu, X.; Xu, Y.; Zhong, Z.; Wu, Y.; Zhao, J.; Wang, Y.; Cheng, H.; Kong, M.; Zhang, F.; Chen, Q.; et al. A Large-Scale Investigation of Hypoxia-Preconditioned Allogeneic Mesenchymal Stem Cells for Myocardial Repair in Nonhuman Primates: Paracrine Activity Without Remuscularization. *Circ. Res.* **2016**, *118*, 970–983. [[CrossRef](#)] [[PubMed](#)]
103. Huber, H.J.; Holvoet, P. Exosomes: Emerging roles in communication between blood cells and vascular tissues during atherosclerosis. *Curr. Opin. Lipidol.* **2015**, *26*, 412–419. [[CrossRef](#)]
104. Wadey, R.M.; Connolly, K.D.; Mathew, D.; Walters, G.; Rees, D.A.; James, P.E. Inflammatory adipocyte-derived extracellular vesicles promote leukocyte attachment to vascular endothelial cells. *Atherosclerosis* **2019**, *283*, 19–27. [[CrossRef](#)]
105. Haney, M.J.; Klyachko, N.L.; Zhao, Y.; Gupta, R.; Plotnikova, E.G.; He, Z.; Patel, T.; Piroyan, A.; Sokolsky, M.; Kabanov, A.V.; et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. *J. Control. Release* **2015**, *207*, 18–30. [[CrossRef](#)] [[PubMed](#)]
106. Ouedraogo, R.; Daumas, A.; Ghigo, E.; Capo, C.; Mege, J.L.; Textoris, J. Whole-cell MALDI-TOF MS: A new tool to assess the multifaceted activation of macrophages. *J. Proteomics* **2012**, *75*, 5523–5532. [[CrossRef](#)] [[PubMed](#)]
107. Fain, J.N.; Bahouth, S.W.; Madan, A.K. TNFalpha release by the nonfat cells of human adipose tissue. *Int. J. Obes. Relat. Metab. Disord.* **2004**, *28*, 616–622. [[CrossRef](#)] [[PubMed](#)]
108. Ren, W.; Hou, J.; Yang, C.; Wang, H.; Wu, S.; Wu, Y.; Zhao, X.; Lu, C. Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery. *J. Exp. Clin. Cancer Res.* **2019**, *38*, 62. [[CrossRef](#)]

109. Ying, W.; Riopel, M.; Bandyopadhyay, G.; Dong, Y.; Birmingham, A.; Seo, J.B.; Ofrecio, J.M.; Wollam, J.; Hernandez-Carretero, A.; Fu, W.; et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. *Cell* **2017**, *171*, 372–384. e12. [[CrossRef](#)] [[PubMed](#)]
110. Freeman, D.W.; Noren Hooten, N.; Eitan, E.; Green, J.; Mode, N.A.; Bodogai, M.; Zhang, Y.; Lehrmann, E.; Zonderman, A.B.; Biragyn, A.; et al. Altered Extracellular Vesicle Concentration, Cargo, and Function in Diabetes. *Diabetes* **2018**, *67*, 2377–2388. [[CrossRef](#)]
111. Mleczko, J.; Ortega, F.J.; Falcon-Perez, J.M.; Wabitsch, M.; Fernandez-Real, J.M.; Mora, S. Extracellular Vesicles from Hypoxic Adipocytes and Obese Subjects Reduce Insulin-Stimulated Glucose Uptake. *Mol. Nutr. Food Res.* **2018**, *62*, 1700917. [[CrossRef](#)] [[PubMed](#)]
112. Campillo, N.; Falcones, B.; Otero, J.; Colina, R.; Gozal, D.; Navajas, D.; Farre, R.; Almendros, I. Differential Oxygenation in Tumor Microenvironment Modulates Macrophage and Cancer Cell Crosstalk: Novel Experimental Setting and Proof of Concept. *Front. Oncol.* **2019**, *9*, 43. [[CrossRef](#)] [[PubMed](#)]
113. Barile, L.; Moccetti, T.; Marban, E.; Vassalli, G. Roles of exosomes in cardioprotection. *Eur. Heart J.* **2017**, *38*, 1372–1379. [[CrossRef](#)] [[PubMed](#)]
114. Frydrychowicz, M.; Kolecka-Bednarczyk, A.; Madejczyk, M.; Yasar, S.; Dworacki, G. Exosomes—Structure, biogenesis and biological role in non-small-cell lung cancer. *Scand. J. Immunol.* **2015**, *81*, 2–10. [[CrossRef](#)] [[PubMed](#)]
115. O'Brien, K.; Breyne, K.; Ughetto, S.; Laurent, L.C.; Breakefield, X.O. RNA delivery by extracellular vesicles in mammalian cells and its applications. *Nat. Rev. Mol. Cell Biol.* **2020**, *21*, 585–606. [[CrossRef](#)]
116. Gozal, E.; Sachleben, L.R., Jr.; Rane, M.J.; Vega, C.; Gozal, D. Mild sustained and intermittent hypoxia induce apoptosis in PC-12 cells via different mechanisms. *Am. J. Physiol. Cell Physiol.* **2005**, *288*, C535–C542. [[CrossRef](#)] [[PubMed](#)]
117. Farre, R.; Almendros, I.; Montserrat, J.M.; Gozal, D.; Navajas, D. Gas Partial Pressure in Cultured Cells: Patho-Physiological Importance and Methodological Approaches. *Front. Physiol.* **2018**, *9*, 1803. [[CrossRef](#)]